Stock listing
NASDAQ:ORIC ORIC Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of ORIC Pharmaceuticals, Inc.
Follow ORIC Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ORIC
$7.36 USD -0.29 (-3.8%)
Close on Nov 20, 2026
- Day range
- $7.28 – $8.00 USDNov 20, 2026
- Volume
- 1.46M sharesNov 20, 2026
- Market cap
- $764.9M USDAt the close on Nov 20, 2026 · price × 103.9M shares outstanding
- 52-week range
- $7.23 – $14.68 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $17.91M USDMedian day 1.23M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ORIC · Home | $7.36 USD | -0.29 (-3.8%) | 1,455,496 | $7.58 | $8.00 | $7.275 | $7.65 | Close on Nov 20, 2026 |
| Frankfurt:4TZ | €6.958 EUR | +0.092 (+1.3%) | — | €6.874 | €6.958 | €6.874 | €6.866 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ORIC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.36 | -0.29 | -3.8% | $7.58 | $8.00 | $7.275 | 1,455,496 | |
| $7.65 | -0.35 | -4.4% | $7.91 | $8.04 | $7.53 | 1,385,239 | |
| $8.00 | +0.48 | +6.4% | $7.71 | $8.01 | $7.58 | 2,000,019 | |
| $7.52 | -0.34 | -4.3% | $7.76 | $7.99 | $7.50 | 1,196,164 | |
| $7.86 | -0.64 | -7.5% | $8.50 | $8.67 | $7.83 | 1,008,732 | |
| $8.50 | -0.50 | -5.6% | $8.77 | $8.86 | $8.45 | 1,178,749 | |
| $9.00 | +0.09 | +1.0% | $8.95 | $9.15 | $8.84 | 773,284 | |
| $8.91 | -0.32 | -3.5% | $9.11 | $9.453 | $8.76 | 1,011,307 | |
| $9.23 | +0.41 | +4.6% | $8.89 | $9.37 | $8.74 | 1,228,508 | |
| $8.82 | +0.33 | +3.9% | $8.61 | $8.93 | $8.50 | 556,747 | |
| $8.49 | -0.85 | -9.1% | $9.32 | $9.34 | $8.46 | 1,390,438 | |
| $9.34 | -0.25 | -2.6% | $9.98 | $10.13 | $9.065 | 2,958,658 | |
| $9.59 | +0.52 | +5.7% | $9.17 | $10.00 | $9.17 | 3,555,380 | |
| $9.07 | -0.17 | -1.8% | $9.285 | $9.38 | $9.00 | 1,922,647 | |
| $9.24 | +0.25 | +2.8% | $8.87 | $9.80 | $8.275 | 2,441,596 | |
| $8.99 | -0.31 | -3.3% | $9.31 | $9.70 | $8.96 | 1,046,758 | |
| $9.30 | +0.30 | +3.3% | $8.80 | $9.33 | $8.60 | 1,413,970 | |
| $9.00 | +0.045 | +0.5% | $8.96 | $9.24 | $8.65 | 4,938,899 | |
| $8.955 | -4.215 | -32.0% | $13.10 | $13.24 | $8.88 | 6,952,473 | |
| $13.17 | -0.46 | -3.4% | $13.10 | $13.49 | $12.73 | 1,388,800 | |
| $13.63 | -0.22 | -1.6% | $13.67 | $14.14 | $13.38 | 1,150,761 | |
| $13.85 | +0.07 | +0.5% | $13.81 | $14.20 | $13.74 | 1,568,849 | |
| $13.78 | +1.06 | +8.3% | $12.79 | $14.31 | $12.52 | 2,019,250 | |
| $12.72 | +0.37 | +3.0% | $12.46 | $12.74 | $12.14 | 1,187,758 | |
| $12.35 | -0.42 | -3.3% | $12.75 | $12.75 | $12.03 | 946,200 | |
| $12.77 | +1.18 | +10.2% | $11.74 | $12.89 | $11.53 | 1,557,455 | |
| $11.59 | +0.28 | +2.5% | $11.35 | $11.84 | $11.20 | 1,791,371 | |
| $11.31 | -0.50 | -4.2% | $11.68 | $11.92 | $11.29 | 1,158,249 | |
| $11.81 | -0.18 | -1.5% | $12.06 | $12.26 | $11.73 | 878,260 | |
| $11.99 | -0.04 | -0.3% | $11.98 | $12.29 | $11.90 | 1,086,585 | |
| $12.03 | +0.02 | +0.2% | $11.87 | $12.20 | $10.93 | 2,695,530 | |
| $12.01 | +0.03 | +0.3% | $11.83 | $12.43 | $11.81 | 790,782 | |
| $11.98 | -0.51 | -4.1% | $12.60 | $12.60 | $11.56 | 2,091,856 | |
| $12.49 | +0.285 | +2.3% | $12.65 | $12.65 | $11.89 | 1,395,684 | |
| $12.21 | -0.315 | -2.5% | $12.72 | $12.93 | $12.17 | 1,232,084 | |
| $12.52 | -0.95 | -7.1% | $13.42 | $13.62 | $12.51 | 1,770,890 | |
| $13.47 | +0.10 | +0.7% | $13.51 | $14.12 | $13.33 | 1,961,192 | |
| $13.37 | +0.10 | +0.8% | $13.23 | $13.42 | $12.76 | 977,262 | |
| $13.27 | +0.11 | +0.8% | $13.14 | $13.72 | $12.76 | 1,515,563 | |
| $13.16 | -0.02 | -0.2% | $13.27 | $13.49 | $12.94 | 2,493,810 | |
| $13.18 | -0.15 | -1.1% | $13.22 | $13.51 | $12.79 | 1,995,576 | |
| $13.33 | -0.17 | -1.3% | $13.94 | $14.00 | $12.94 | 1,717,561 | |
| $13.50 | +0.83 | +6.6% | $12.73 | $13.53 | $12.54 | 1,157,584 | |
| $12.67 | -0.12 | -0.9% | $12.98 | $13.01 | $12.50 | 835,961 | |
| $12.79 | -0.09 | -0.7% | $12.81 | $12.91 | $12.48 | 3,090,944 | |
| $12.88 | +0.34 | +2.7% | $12.87 | $13.22 | $12.66 | 1,156,336 | |
| $12.54 | +0.18 | +1.5% | $12.38 | $12.84 | $12.17 | 1,609,372 | |
| $12.36 | -0.29 | -2.3% | $12.60 | $12.65 | $11.95 | 2,052,561 | |
| $12.65 | +0.61 | +5.1% | $12.02 | $12.69 | $11.86 | 1,618,209 | |
| $12.04 | -0.03 | -0.2% | $12.26 | $12.41 | $12.00 | 1,063,007 | |
| $12.07 | -0.43 | -3.4% | $12.64 | $12.79 | $12.01 | 1,027,306 | |
| $12.50 | -0.12 | -1.0% | $12.50 | $13.00 | $12.31 | 1,669,253 | |
| $12.62 | -0.24 | -1.9% | $12.67 | $12.87 | $12.54 | 955,399 | |
| $12.86 | +0.12 | +0.9% | $12.51 | $12.99 | $12.51 | 991,453 | |
| $12.74 | -0.39 | -3.0% | $13.17 | $13.41 | $12.59 | 916,441 | |
| $13.13 | +0.24 | +1.9% | $12.97 | $13.53 | $12.83 | 1,546,226 | |
| $12.89 | -0.10 | -0.8% | $12.82 | $13.06 | $12.77 | 646,365 | |
| $12.99 | -0.25 | -1.9% | $13.18 | $13.18 | $12.67 | 1,158,805 | |
| $13.24 | -0.50 | -3.6% | $13.59 | $13.93 | $13.20 | 765,429 | |
| $13.74 | -0.17 | -1.2% | $13.96 | $14.25 | $13.65 | 1,060,961 | |
| $13.91 | +0.08 | +0.6% | $13.74 | $13.97 | $13.48 | 1,123,808 | |
| $13.83 | +0.37 | +2.7% | $13.71 | $14.15 | $13.52 | 1,168,791 | |
| $13.46 | -0.74 | -5.2% | $14.16 | $14.52 | $13.44 | 1,110,088 | |
| $14.20 | +0.32 | +2.3% | $14.00 | $14.34 | $13.81 | 970,493 | |
| $13.88 | -0.77 | -5.3% | $14.32 | $14.52 | $13.77 | 1,176,680 |
- Ticker
- NASDAQ:ORIC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates
Latest deck · Oct 23, 2026
Corporate Update (October 2026)
Corporate update · 40 slides
Latest news
ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates
Nov 16, 2026
Closed $8.00 (+6.4%) on Nov 17, 2026
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Nov 6, 2026
Closed $9.23 (+4.6%) on Nov 9, 2026
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 3, 2026
Closed $9.34 (-2.6%) on Nov 4, 2026
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
Oct 23, 2026
Closed $13.17 (-3.4%) on Oct 23, 2026
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
Oct 23, 2026
Closed $13.17 (-3.4%) on Oct 23, 2026
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
Oct 19, 2026
Closed $12.72 (+3.0%) on Oct 19, 2026
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
Oct 5, 2026
Closed $11.98 (-4.1%) on Oct 6, 2026
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Aug 3, 2026
Closed $13.47 (+27.1%) on Aug 4, 2026
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Jul 20, 2026
Closed $10.42 (-2.9%) on Jul 20, 2026
ORIC Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 28 in the last 12 months · 137 in all · newest Nov 16, 2026 · oldest 2020
- Calls
- 1 call with a replay · 1 with a transcript · latest Mar 21, 2022
- Decks
- 12 decks · latest Oct 23, 2026
Where ORIC Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ORIC · Home listing · This page | NASDAQ | United States | USD |
| LS Exchange:A2P208 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2P208 | Lang & Schwarz | Germany | EUR |
| gettex:4TZ | gettex | Germany | EUR |
| BOATS:ORIC | BOATS | United States | USD |
| Tradegate:4TZ | Tradegate | Germany | EUR |
| Dusseldorf:4TZ | Dusseldorf | Germany | EUR |
| Frankfurt:4TZ | Frankfurt | Germany | EUR |
| Hamburg:4TZ | Hamburg | Germany | EUR |
| Munich:4TZ | Munich | Germany | EUR |
| Stuttgart:4TZ | Stuttgart | Germany | EUR |
Valuation
Price/book 2.3× against a median of 3.4×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $503.6M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.22
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ORIC Pharmaceuticals, Inc. · NASDAQ:ORIC | US$764.9M | US$503.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.22 |
| Arbutus Biopharma Corporation · NASDAQ:ABUS | US$796.4M | US$458.9M | 3.6× | 2.5× | 3.1× | 9.3× | 121.2% | 0.0× | 1.10 |
| Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595 | US$787.5M | US$518.8M | n/a | 26.5× | n/a | 3.3× | n/a | 0.0× | n/a |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335 | US$778.7M | US$599.6M | n/a | n/a | n/a | 5.5× | n/a | 0.0× | n/a |
| Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD | US$778.1M | US$702.9M | 5.2× | 1.8× | n/a | n/a | 37.4% | n/a | 1.16 |
| Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX | US$772.7M | US$695.6M | n/a | 2.4× | n/a | n/a | −72.4% | n/a | 0.64 |
| MeiraGTx Holdings plc · NASDAQ:MGTX | US$766.4M | US$715.6M | 9.8× | 1.8× | 3.7× | 3.6× | 19.5% | 0.6× | 1.57 |
| Inventiva SA · EURONEXT:IVA | US$760.9M | US$577.3M | n/a | 117× | n/a | 11.8× | n/a | 1.1× | n/a |
| Rigel Pharmaceuticals, Inc. · NASDAQ:RIGL | US$754.9M | US$663.4M | 2.5× | 2.3× | 8.3× | 1.7× | 106.6% | 0.0× | 1.02 |
| Obsidian Therapeutics, Inc. · NASDAQ:OBX | US$741.3M | US$530.4M | 13.0× | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Monte Rosa Therapeutics, Inc. · NASDAQ:GLUE | US$738.3M | US$196.8M | n/a | 2.8× | n/a | 1.5× | −186.2% | 0.1× | 0.92 |
| Median of the others | US$769.6M | US$588.5M | 5.2× | 2.5× | 3.7× | 3.4× | 28.4% | 0.0× | 1.06 |
Forecasts
12 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 21.79 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.59 · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Angie You | Board Member, CEO of Architect Therapeutics |
| Jacob Chacko | President, Chief Executive Officer |
| Steve L. Hoerter | Board Member, Chairman and CEO of MBX Biosciences |
| Dominic Piscitelli | Chief Financial Officer |
| Christian V. Kuhlen | General Counsel and Chief Compliance Officer |
| Dan Iazzetti | Vice President, Head of People |
| Edna Chow Maneval | Executive Vice President, Clinical Development |
| Keith Lui | Senior Vice President, Commercial and Medical Affairs |
| Kevin Brodbeck | newly established role of Chief Technical Officer |
| Lori Friedman | Chief Scientific Officer |
| Matthew Panuwat | Chief Business Officer |
| Pratik Multani | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Richard Heyman | Chairman |
| Steve L. Hoerter | Board Member, Chairman and CEO of MBX Biosciences |
| Angie You | Board Member, CEO of Architect Therapeutics |
| Jacob Chacko | President, Chief Executive Officer |
| Lori Kunkel | Board Member |
| Mardi C. Dier | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| ORIC Pharmaceuticals (NASDAQ:ORIC) Q4 2021 Earnings Call | Mon, Mar 21, 2022 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | +6.4% |
| Q2 2026 | Aug 3, 2026 · After close | +27.1% |
| Q1 2026 | May 4, 2026 · After close | −0.6% |
| Q4 2025 | Mar 24, 2026 | +5.1% |
| Q3 2025 | Nov 13, 2025 · After close | +0.5% |
| Q2 2025 | Aug 12, 2025 · After close | +3.3% |
| Q1 2025 | May 5, 2025 · After close | −11.6% |
| Q4 2024 | Mar 10, 2025 · Before open | −4.6% |
| Q3 2024 | Nov 12, 2024 · After close | +0.1% |
| Q2 2024 | Aug 12, 2024 · After close | +6.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 · After close | +2.6% |
| Q4 2023 | Mar 11, 2024 · After close | −4.5% |
| Q3 2023 | Nov 6, 2023 · After close | −0.7% |
| Q2 2023 | Aug 10, 2023 · After close | +11.0% |
| Q1 2023 | May 8, 2023 · After close | −2.5% |
| Q4 2022 | Mar 16, 2023 · After close | −8.6% |
| Q3 2022 | Nov 7, 2022 · After close | +3.7% |
| Q2 2022 | Aug 11, 2022 · After close | +4.5% |
| Q1 2022 | May 9, 2022 · After close | +5.2% |
| Q4 2021 | Mar 21, 2022 · After close | −28.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (October 2026) | Corporate update | 40 slides | Oct 23, 2026 |
| Investor Presentation (September 2026) | Investor deck | 49 slides | September 2026 |
| Corporate Update (March 2026) | Corporate update | 44 slides | Mar 31, 2026 |
| Technical Presentation (December 2025) | Technical | 43 slides | Dec 8, 2025 |
| ESMO Asia 2025 | Conference | 19 slides | Dec 6, 2025 |
| Technical Presentation (December 2025) | Technical | 19 slides | Dec 6, 2025 |
| ESMO 2025 Mini Oral Presentation | Conference | 10 slides | Dec 5, 2025 |
| Technical Presentation (November 2025) | Technical | 9 slides | Nov 13, 2025 |
| Investor Presentation (January 2025) | Investor deck | 43 slides | Jan 13, 2025 |
| Investor Presentation (January 2024) | Investor deck | 43 slides | Jan 9, 2024 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2021 Earnings Presentation | Earnings | 15 slides | Mar 21, 2022 |
| Investor Presentation (January 2021) | Investor deck | 41 slides | Jan 11, 2021 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Closed: US$20M raised | Feb 23, 2026 |
| At-the-market programme of common stock Closed: US$119M raised | Aug 12, 2025 |
| Private placement of common stock (or pre-funded warrants in lieu thereof) Announced: about US$125M · US$6.5 a share Buyers: SR One (leads the financing); Point72; Viking Global Investors; Venrock Healthcare Capital Partners; NEA; Nextech; Vivo Capital; NEXTBio Capital Use of proceeds: Research and development of clinical-stage product candidates and research programs, working capital and general corporate purposes | May 28, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Apr 23, 2020.
- Price
- US$16.00 a share
- Shares offered
- 7,500,000 shares of common stock
- Offering size
- US$120 million
- Underwriters' option
- Up to 1,125,000 more shares
- Underwriters
- J.P. Morgan, Citigroup, Jefferies, Guggenheim Securities · In the order on the cover
- Shares delivered
- On or about Apr 28, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 13, 2019 |
| Filed publicly | Feb 28, 2020 |
| Amended twice | Newest Apr 23, 2020 |
| Shares registered with an exchange | Apr 20, 2020 |
| Declared effective by the SEC | Apr 23, 2020 |
| Final prospectus, with the price | Apr 24, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 24, 2020 |
| EFFECT · Notice that a registration is effective | Apr 23, 2020 |
| S-1MEF · Registration of more shares for the same offering | Apr 23, 2020 |
| CERT · Exchange's certificate of listing | Apr 23, 2020 |
| CORRESP · Letter to the SEC | Apr 23, 2020 |
| S-1/A · Registration statement, amended | Apr 23, 2020 |
| UPLOAD · Letter from the SEC | Apr 22, 2020 |
| CORRESP · Letter to the SEC | Apr 21, 2020 |
| CORRESP · Letter to the SEC | Apr 21, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 20, 2020 |
All 21 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Apr 20, 2020 |
| S-1/A · Registration statement, amended | Apr 20, 2020 |
| UPLOAD · Letter from the SEC | Mar 9, 2020 |
| CORRESP · Letter to the SEC | Mar 3, 2020 |
| CORRESP · Letter to the SEC | Feb 28, 2020 |
| S-1 · Registration statement | Feb 28, 2020 |
| UPLOAD · Letter from the SEC | Feb 3, 2020 |
| DRSLTR · Letter to the SEC with a draft | Jan 24, 2020 |
| DRS/A · Draft registration statement, amended | Jan 24, 2020 |
| UPLOAD · Letter from the SEC | Jan 9, 2020 |
| DRS · Draft registration statement | Dec 13, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 24, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 1.22M | 1.11M | 1.03M | 966.0K | 897.0K | 970.0K | 1.00M | 900.0K | 900.0K |
| Gross profit | -1.22M | -1.11M | -1.03M | -966.0K | -897.0K | -970.0K | -1.00M | -900.0K | -900.0K |
| Research and development | 109.8M | 114.1M | 85.2M | 61.7M | 56.9M | 35.9M | 22.8M | 19.0M | 19.1M |
| Selling, general and administrative | 33.2M | 28.8M | 25.6M | 25.1M | 22.0M | 13.4M | 5.72M | 3.35M | 3.42M |
| Operating income | -143.0M | -142.9M | -110.8M | -91.8M | -78.9M | -74.2M | -28.6M | -22.4M | -22.5M |
| Depreciation and amortization | 1.22M | 1.11M | 1.03M | 966.0K | 897.0K | 970.0K | 1.03M | 903.0K | 900.0K |
| EBITDA | -141.8M | -141.8M | -109.7M | -90.8M | -78.0M | -73.2M | -27.5M | -21.5M | -21.6M |
| Interest expense | 2.65M | 141.0K | 306.0K | 1.69M | 1.01M | 0 | |||
| Income before tax | -129.5M | -127.8M | -100.7M | -89.1M | -78.7M | -73.7M | -26.9M | -21.4M | -22.0M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income | -129.5M | -127.8M | -100.7M | -89.1M | -78.7M | -73.7M | -26.9M | -21.4M | -22.0M |
| Earnings per share, basic | -1.47 | -1.83 | -1.96 | -2.25 | -2.07 | -3.36 | -14.15 | -12.32 | -15.62 |
| Earnings per share, diluted | -1.47 | -1.83 | -1.96 | -2.25 | -2.07 | -3.36 | -14.15 | -12.32 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 45.7M | 59.4M | 23.4M | 66.8M | 226.0M | 78.4M | 89.2M | 42.6M | 25.8M |
| Short-term investments | 235.8M | 196.6M | 184.8M | 139.4M | 11.0M | 215.2M | |||
| Current assets | 288.5M | 262.3M | 212.6M | 210.5M | 240.5M | 296.7M | 90.0M | 43.7M | 26.6M |
| Property, plant and equipment | 2.42M | 2.92M | 2.86M | 3.25M | 2.41M | 1.98M | 2.24M | 2.51M | 2.90M |
| Total assets | 408.9M | 274.1M | 252.0M | 247.2M | 298.6M | 299.0M | 94.1M | 46.7M | 30.0M |
| Accounts payable | 3.82M | 1.55M | 944.0K | 1.32M | 1.89M | 757.0K | 152.0K | 446.0K | 940.0K |
| Current liabilities | 20.4M | 24.8M | 20.5M | 15.4M | 15.2M | 9.00M | 5.35M | 2.60M | 2.61M |
| Total debt | 3.33M | 3.18M | 10.2M | 12.1M | 10.5M | ||||
| Total liabilities | 24.5M | 31.0M | 27.9M | 24.8M | 25.7M | 9.22M | 6.12M | 111.2M | 4.30M |
| Shareholders' equity | 384.4M | 243.1M | 224.1M | 222.4M | 273.0M | 289.8M | -90.1M | -64.4M | 25.7M |
| Shares outstanding | 98.5M | 71.0M | 54.9M | 45.1M | 39.4M | 36.7M | 1.98M | 39.4M | 1.41M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -111.0M | -112.7M | -85.7M | -75.1M | -59.5M | -45.3M | -23.5M | -20.7M | -20.8M |
| Capital spending | -712.0K | -1.19M | -849.0K | -2.08M | -939.0K | -667.0K | -768.0K | -525.0K | -486.0K |
| Free cash flow | -111.7M | -113.8M | -86.5M | -77.2M | -60.5M | -45.9M | -24.3M | -21.2M | -21.3M |
| Cash from investing | -148.0M | 22.1M | -43.4M | -109.2M | 158.4M | -216.0M | -768.0K | -508.0K | -292.0K |
| Cash from financing | 245.3M | 126.5M | 85.7M | 25.2M | 49.1M | 250.5M | 70.8M | 38.0M | 260.0K |
| Share buybacks | 545.0K | 51.0M | 271.8M | 70.9M | 38.0M | ||||
| Change in cash | -13.7M | 36.0M | -43.4M | -159.2M | 148.0M | -10.7M | 46.5M | 16.8M | -20.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 23, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2026 | Results | SEC |
| S-8 · Registration statement for employee plans | Jul 30, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 22, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 31, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 23, 2026 | Current report | SEC |
| 424B5 · Prospectus | Feb 23, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 23, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 23, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 23, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 22, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 24, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jun 23, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 17, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| S-3 · Registration statement | Jun 11, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 6, 2025 | Other filings | SEC |
| D | Jun 6, 2025 | Other filings | SEC |
| SCHEDULE 13D · Big-stake notice | Jun 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 4, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 30, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 28, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 20, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 14, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 25, 2025 | Current report | SEC |
| 10-K · Annual report | Feb 18, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 18, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2024 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 29, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 29, 2024 | Management or board change | SEC |
| S-3ASR · Registration statement | Mar 11, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 11, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 6, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 8, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 6, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 5, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Feb 1, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Jan 31, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 31, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Jan 30, 2024 | Big-stake notice | SEC |
| D | Jan 30, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Jan 29, 2024 | Big-stake notice | SEC |
| S-3 · Registration statement | Jan 26, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Jan 25, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 22, 2024 | Material contract | SEC |
| 8-K · Current report | Jan 9, 2024 | Results | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 29, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 26, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 22, 2023 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| S-3 · Registration statement | Dec 15, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2023 | Results | SEC |
| 8-K · Current report | Oct 23, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jul 7, 2023 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 5, 2023 | Other filings | SEC |
This page holds 200 of 428 filings. Open Filings
Cap table
Built by 6ix from ORIC Pharmaceuticals, Inc.’s releases · as of Nov 9, 2026
- Common shares
- 103,931,597
- Fully diluted
- 103,948,797
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 103,931,597 | Nov 9, 2026 |
| Options and RSUs | 17,200 | Nov 2, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · expiry not stated |
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 9, 2026 | 103,931,597 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Carl Gordon Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past) | Director · Apr 23, 2020 – Jun 16, 2021 · Past |
| Richard Heyman Other companies: Enliven Therapeutics, Inc. (Director · Since at least Feb 23, 2023); PMV Pharmaceuticals, Inc. (Director · Since at least Sep 24, 2020); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Kineta Inc. (Director · Dec 22, 2020 – Jun 2, 2021 · Past); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Tango Therapeutics, Inc. (Director · Sep 2, 2020 – Sep 2, 2020 · Past); Gritstone bio, Inc. (Director · Sep 27, 2018 – Jun 17, 2022 · Past) | Chairman · Since at least Apr 23, 2020 |
| Mardi C. Dier Other companies: Madrigal Pharmaceuticals, Inc. (EVP and CFO · Since at least Mar 11, 2024); Prelude Therapeutics Incorporated (Director · Since at least Sep 24, 2020); Acelyrin, Inc. (CFO and CBO · May 4, 2023 – May 9, 2023 · Past); Ultragenyx Pharmaceutical Inc. (CFO & Executive Vice President · Oct 12, 2020 – Oct 14, 2022 · Past); Adamas Pharmaceuticals Inc (Director · Oct 10, 2017 – Jun 2, 2021 · Past); Portola Pharmaceuticals Inc (EVP and CFO · May 21, 2013 – Jul 2, 2020 · Past) | Board Member · Since at least Apr 23, 2020 |
| Richard H. Scheller Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Alector, Inc. (Board Member · Since at least Feb 6, 2019); 23Andme Holding Co (Director · Jun 16, 2021 – Aug 26, 2024 · Past); BridgeBio Pharma, Inc. (Director · Jun 27, 2019 – Feb 16, 2023 · Past); Xenon Pharmaceuticals Inc. (Director · Mar 16, 2015 – Sep 16, 2019 · Past); Genentech Inc (EVP-RESEARCH · Jan 13, 2006 – Mar 26, 2009 · Past) | Director · Apr 23, 2020 – May 20, 2021 · Past |
| Steve L. Hoerter Other companies: MBX Biosciences, Inc. (Chairman, President and CEO, Director · Since at least Apr 7, 2025); C4 Therapeutics, Inc. (Director · Since at least Nov 19, 2024); Constellation Pharmaceuticals Inc (Director · Sep 4, 2018 – Jul 15, 2021 · Past); Deciphera Pharmaceuticals LLC (President and CEO, Director · May 17, 2018 – Jun 11, 2024 · Past); Agios Pharmaceuticals, Inc. (Chief Commercial Officer · Feb 16, 2016 – Mar 1, 2019 · Past); Clovis Oncology Inc (See Remarks · Nov 15, 2011 – Mar 5, 2015 · Past) | Board Member, Chairman and CEO of MBX Biosciences · Since at least Aug 13, 2021 |
| Lori Kunkel Other companies: Enliven Therapeutics, Inc. (Director · Since at least Apr 8, 2024); Nurix Therapeutics, Inc. (Director · Jul 23, 2020 – May 19, 2025 · Past); Tocagen Inc (Director · Jun 21, 2018 – Oct 4, 2019 · Past); Curis, Inc. (Director · Jan 22, 2018 – Jan 31, 2022 · Past); Loxo Oncology Inc (Director · Nov 2, 2017 – Feb 15, 2019 · Past) | Director · Since at least Jun 9, 2020 |
| Peter Svennilson Other companies: RAPT Therapeutics Inc (Director · Jun 18, 2020 – May 28, 2021 · Past); Revolution Medicines, Inc. (Director · Jun 17, 2020 – Apr 26, 2021 · Past); Gritstone bio, Inc. (Director · Jun 19, 2019 – Jun 19, 2019 · Past); NGM Biopharmaceuticals Inc (Director · Apr 3, 2019 – Apr 8, 2020 · Past) | Director · Apr 23, 2020 – Jun 16, 2021 · Past |
| Angie You Other companies: Attovia Therapeutics, Inc. (Director · Since at least Aug 4, 2026); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Sierra Oncology Inc (Chief Bus. & Strat. Officer · Jul 15, 2015 – Mar 6, 2018 · Past) | Director · Since at least Nov 9, 2021 |
| Pratik Multani Other companies: Erasca, Inc. (Director · Since at least Jul 15, 2021); Chimerix Inc (Director · Feb 21, 2020 – Apr 21, 2025 · Past); Fate Therapeutics, Inc. (Chief Medical Officer · Sep 30, 2013 – Jan 5, 2015 · Past) | Chief Medical Officer · Since at least Apr 23, 2020 |
| Jacob Chacko Other companies: 4D Molecular Therapeutics, Inc. (Director · Since at least Dec 10, 2020) | PRESIDENT AND CEO, Director · Since at least Feb 1, 2021 |
All 18 people
| Person | Seat |
|---|---|
| Christian V. Kuhlen | General Counsel and Chief Compliance Officer · Since at least Nov 5, 2026 |
| Dan Iazzetti | Vice President, Head of People · Since at least Nov 5, 2026 |
| Dominic Piscitelli | Chief Financial Officer · Since at least Jul 20, 2022 |
| Edna Chow Maneval | Executive Vice President, Clinical Development · Since at least Nov 5, 2026 |
| Keith Lui | Senior Vice President, Commercial and Medical Affairs · Since at least Feb 18, 2025 |
| Kevin Brodbeck | newly established role of Chief Technical Officer · Since at least Nov 13, 2025 |
| Lori Friedman | Chief Scientific Officer · Since at least Oct 23, 2026 |
| Matthew Panuwat | Chief Business Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about ORIC Pharmaceuticals, Inc.